Jason Hoitt insider trades

Open-market stock purchases and sales by Jason Hoitt, Chief Patient Officer at Stoke Therapeutics, Inc, from SEC Form 4 filings since Dec 19, 2018.

Recent trades

DateStockTradeValue
Mar 18, 2026STOK Stoke Therapeutics, IncSold$55.1K
Mar 18, 2026STOK Stoke Therapeutics, IncSold$4.4K
Mar 18, 2026STOK Stoke Therapeutics, IncSold$986
Mar 17, 2026STOK Stoke Therapeutics, IncSold$33.8K
Mar 17, 2026STOK Stoke Therapeutics, IncSold$25K
Mar 15, 2026STOK Stoke Therapeutics, IncBought (not open market)—
Feb 17, 2026STOK Stoke Therapeutics, IncBought (not open market)—
Feb 17, 2026STOK Stoke Therapeutics, IncBought (not open market)—

Companies traded

  • STOK Stoke Therapeutics, Inc: 5 sales, last Mar 18, 2026
  • PRVB Provention Bio, Inc: 1 buy, 1 sale, last Apr 27, 2023
  • DOVA Dova Pharmaceuticals Inc: 6 sales, last Nov 12, 2019

Get free alerts when Jason Hoitt files a new trade →